Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.
Abivax is advancing obefazimod, a first-in-class oral therapy for UC and CD, with major upcoming data catalysts. Click here ...
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% ...
"Renewing our SOC 2 Type II audit is an important validation of the security framework we've established at Yosi Health," ...
San Marcos nonprofit Wounded Warrior Homes is expanding housing and mental health services for veterans, including a brain ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple ...
Dr. Ajay Nooka, director of the Myeloma program at Winship Cancer Institute of Emory University, simplifies the International ...
Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results